Merkel cell carcinoma: treatment with bleomycin

Area of Science:

• Oncology
• Dermatology
• Virology

Background:

• Merkel cell carcinoma (MCC) is an aggressive skin cancer with a high mortality rate, often presenting on sun-exposed skin in the elderly.
• Increased incidence is observed in immunocompromised individuals, such as transplant recipients and AIDS patients, with a suspected association with polyoma virus.
• Standard treatment involves surgery and radiation, with chemotherapy for metastatic disease, though systemic protocols have limited success.

Observation:

• Four cases of stage-I Merkel cell carcinoma were treated with surgery followed by intralesional bleomycin.
• Follow-up for up to five years revealed no evidence of recurrence or metastasis in these cases.
• One case receiving post-operative radiation experienced recurrence, suggesting limitations of radiation therapy.

Findings:

• Intralesional bleomycin demonstrated complete tumor regression with minimal scarring and long-term cure in stage-I MCC.
• This treatment approach appears more effective than conventional radiation therapy in preventing recurrence.
• Bleomycin's direct antiviral properties may contribute to its efficacy against MCC, potentially by targeting the associated polyoma virus.

Implications:

• Intralesional bleomycin represents a potentially superior treatment option for stage-I Merkel cell carcinoma, offering improved outcomes and reduced scarring.
• Further research into bleomycin's antiviral mechanisms could lead to novel therapeutic strategies for virus-associated cancers.
• This study highlights the importance of exploring localized and targeted therapies for aggressive skin malignancies like MCC.